Stethoscope

Company

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules.

IO Biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting IDO and PD-L1 in clinical development and several compounds finalizing preclinical phase.

IO Biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

IO Biotech is located in Copenhagen, Denmark.

Pipette

Technology

IO Biotech has a unique and novel technology platform, T-win, for developing immune modulating anti-cancer therapies.

Through targeting cells expressing immune regulating proteins, a dual mode of action of our immune modulating anti-cancer therapies is obtained:

• Recognition and elimination of tumor cells
• Recogntion of immune suppressive cells

The T-win technology is therefore unique in that the compounds directly target tumor cells and micro environment and initiate a dynamic process of activating the host immune system, which can then be exploited by concurrent or subsequent therapies.

More information

Scales

Pipeline

IO Biotech has an advanced clinical portfolio of first-in-class immune modulating anti-cancer therapies with three compounds in phase I or phase I/II.

Our lead compound IO102, targeting IDO, has shown promising anti-tumor efficacy in a phase I clinical trial in NSCLC and a large phase II combination trial is soon to be initiated. Our second lead, IO103, targets PD-L1 and three clinical trails are ongoing in multiple myeloma, follicular lymphoma and melanoma. In addition, several compounds are in late pre-clinical phase

Our preclinical data support a dual mode of action of T-win platform, where our immune modulating anti-cancer therapies both eliminate immune-suppressive cells and cancer cells expressing the target. Clinical data from our trials shows favorable safety profile as well as promising signs of efficacy.

Our immune modulating anti-cancer therapies can potentially offer the ideal safe and effective add-on treatment to e.g. check point inhibitors - or as monotherapy for a niche indication.

More information